Atlas Three · Medicine Atlas · 01-modern

Checkpoint Inhibitors

Monoclonal antibodies blocking immune checkpoint receptors (PD-1, PD-L1, CTLA-4) that tumors exploit to suppress T cell killing. Nobel Prize 2018 (Allison & Honjo). Transform survival in melanoma, NSCLC, MSI-H tumors, and 15+ cancer types.

Also known as: immune checkpoint inhibitors, ICI, anti-PD-1, anti-PD-L1, anti-CTLA-4, pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, Keytruda, Opdivo, Yervoy

01-modernStream
—Route
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
checkpoint-inhibitors

Checkpoint Inhibitors

Monoclonal antibodies blocking immune checkpoint receptors (PD-1, PD-L1, CTLA-4) that tumors exploit to suppress T cell killing. Nobel Prize 2018 (Allison & Honjo). Transform survival in melanoma, NSCLC, MSI-H tumors, and 15+ cancer types.

Entry Metadata

FieldValue
IDcheckpoint-inhibitors
NameCheckpoint Inhibitors
Statusdraft
Last reviewed2026-06-06
Stream01-modern
Drug classimmune checkpoint inhibitor monoclonal antibody

Cross-Atlas Connections

targetsT Cytotoxic Cell targetsT Helper Cell modulatesTnf Alpha modulatesImmune System treatsMelanoma targetsPd 1 targetsCtla 4

Sources